FILGRASTIM (fil-gras'tim) Neupogen Classifications: blood formers, coagulators, and anticoagulants; hematopoietic growth factor Prototype: Epoetin alfa Pregnancy Category: C |
300 mcg/mL injection
Human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Endogenous G-CSF regulates the production of neutrophils within the bone marrow; not species specific and primarily affects neutrophil proliferation, differentiation and selected end-cell functional activity (including enhanced phagocytic activity, antibody-dependent killing, and the increased expression of some functions associated with cell-surface antigens).
Increases neutrophil proliferation and differentiation within the bone marrow.
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever; to decrease neutropenia associated with bone marrow transplant; to treat chronic neutropenia; to mobilize peripheral blood stem cells (PBSCs) for autologous transplantation.
Hypersensitivity to Escherichia coliderived proteins, simultaneous administration with chemotherapy, and myeloid cancers.
Pregnancy (category C), lactation.
Neutropenia Adult/Child: IV 5 mcg/kg/d by 30 min infusion, may increase by 5 mcg/kg/d (max: 30 mcg/kg/d) SC 5 mcg/kg/d as single dose, may increase by 5 mcg/kg/d (max: 20 mcg/kg/d) |
Subcutaneous & Intravenous
PREPARE: Intermittent/Continuous: May dilute with 1050 mL D5W to yield 15 mcg/mL or greater. If more diluent is used to yield concentrations of 515 mcg/mL, 2 mL of 5% human albumin must be added for each 50 mL D5W (prior to adding filgrastim) to prevent adsorption to plastic IV infusion materials. ADMINISTER: Intermittent: Give a single dose over 1530 min. Continuous: Give a single dose over 424 h. INCOMPATIBILITIES Y-site: Amphotericin B, cefepime, cefoperazone, cefotaxime, cefoxitin, ceftizoxime, ceftriaxone, cefuroxime, clindamycin, dactinomycin, etoposide, fluorouracil, furosemide, gentamicin, heparin, imipenem, mannitol, methylprednisolone, metronidazole, mitomycin, piperacillin, prochlorperazine, thiotepa. |
Elevations in leukocyte alkaline phosphatase, serum alkaline phosphatase, lactate dehydrogenase, and uric acid have been reported. These elevations appear to be related to increased bone marrow activity.
Assessment & Drug Effects
Patient & Family Education